Search

Your search keyword '"Quarato P.P."' showing total 17 results
Start Over Author "Quarato P.P."
17 results on '"Quarato P.P."'

2. Rundown of GABA type A receptors is a dysfunction associated with human drug-resistant mesial temporal lobe epilepsy

Author

Ragozzino, D., Palma, E., Di Angelatonio, S., Amici, M., Mascia, A., Arcella, A., Giangaspero, F., Cantore, G. Di Gennaro, G., Manfredi, M., Esposito, V. Quarato, P.P., Miledi, R., and Eusebi, F.

Subjects
Epilepsy -- Research, Epilepsy -- Care and treatment, Drug resistance -- Research, Science and technology
Abstract

Pharmacotherapeutic strategies have been difficult to develop for several forms of temporal lobe epilepsy, which are consequently treated by surgical resection. To examine this problem, we have studied the properties of transmitter receptors of tissues removed during surgical treatment. We find that when cell membranes, isolated from the temporal neocortex of patients afflicted with drug-resistant mesial temporal lobe epilepsy (TLE), are injected into frog oocytes they acquire GABA type A receptors (GABAA-receptors) that display a marked rundown during repetitive applications of GABA. In contrast, GABAA-receptor function is stable in oocytes injected with cell membranes isolated from the temporal lobe of TLE patients afflicted with neoplastic, dysgenetic, traumatic, or ischemic temporal lesions (lesional TLE, LTLE). Use-dependent GABAA-receptor rundown is also found in the pyramidal neurons of TLE neocortical slices and is antagonized by BDNF. Pyramidal neurons in cortical slices of a traumatic LTLE patient did not show GABAA-receptor rundown. However, the apparent affinity of GABAA-receptor in oocytes microtransplanted with membranes from all of the epileptic patients studied was smaller than the affinity of receptors transplanted from the nonepileptic brain. We conclude that the use-dependent rundown of neocortical GABAAreceptor represents a TLE-specific dysfunction, whereas the reduced affinity may be a general feature of brains of both TLE and LTLE patients, and we speculate that our findings may help to develop new treatments for TLE and LTLE. human slices | Xenopus oocytes

Published
2005

4. BDNF modulates [GABA.sub.A] receptors microtransplanted from the human epileptic brain to Xenopus oocytes

Author

Palma, E., Torchia, G., Limatola, C., Trettel, F., Arcella, A., Cantore, G., Di Gennaro, G., Manfredi, M., Esposito, V., Quarato, P.P., Miledi, R., and Eusebi, F.

Subjects
Temporal lobe epilepsy -- Research, Temporal lobe epilepsy -- Genetic aspects, Science and technology
Abstract

Cell membranes isolated from brain tissues, obtained surgically from six patients afflicted with drug-resistant temporal lobe epilepsy and from one nonepileptic patient afflicted with a cerebral oligodendroglioma, were injected into frog oocytes. By using this approach, the oocytes acquire human GAB[A.sub.A] receptors, and we have shown previously that the 'epileptic receptors' (receptors transplanted from epileptic brains) display a marked run-down during repetitive applications of GABA. It was found that exposure to the neurotrophin BDNF increased the amplitude of the 'GABA currents' (currents elicited by GABA) generated by the epileptic receptors and decreased their run-down; both events being blocked by K252A, a neurotrophin tyrosine kinase receptor B inhibitor. These effects of BDNF were not mimicked by nerve growth factor. In contrast, the GAB[A.SUB.A] receptors transplanted from the nonepileptic human hippocampal uncus (obtained during surgical resection as part of the nontumoral tissue from the oligodendroglioma margins) or receptors expressed by injecting rat recombinant [alpha]1[beta]2[gamma]2 GAB[A.SUB.A] receptor subunit cDNAs generated GABA currents whose time-course and run-down were not altered by BDNF. Loading the oocytes with the [Ca.sup.2+] chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetate-acetoxymethyl ester (BAPTA-AM), or treating them with Rp-8-Br-cAMP, an inhibitor of the cAMP-dependent PKA, did not alter the GABA currents. However, staurosporine (a broad spectrum PK inhibitor), bisindolylmaleimide I (a PKC inhibitor), and U73122 (a phospholipase C inhibitor) blocked the BDNF-induced effects on the epileptic GABA currents. Our results indicate that BDNF potentiates the epileptic GAB[A.SUB.A] currents and antagonizes their use-dependent run-down, thus strengthening GABAergic inhibition, probably by means of activation of tyrosine kinase receptor B receptors and of both PLC and PKC. microtransplantation into Xenopus oocytes | temporal lobe epilepsy

Published
2005

5. Phosphatase inhibitors remove the run-down of [gamma]-aminobutyric acid type A receptors in the human epileptic brain

Author

Palma, E., Ragozzino, D.A., Di Angelantonio, S., Spinelli, G., Trettel, F., Martinez-Torres, A., Torchia, G., Arcella, A., Di Gennaro, G., Quarato, P.P., Esposito, V., Cantore, G., Miledi, R., and Eusebi, F.

Subjects
Temporal lobe epilepsy -- Research, Temporal lobe epilepsy -- Drug use, Science and technology
Abstract

The properties of [gamma]-aminobutyric acid (GABA) type A receptors (GAB[A.sub.A] receptors) microtransplanted from the human epileptic brain to the plasma membrane of Xenopus oocytes were compared with those recorded directly from neurons, or glial cells, in human brains slices. Cell membranes isolated from brain specimens, surgically obtained from six patients afflicted with drug-resistant temporal lobe epilepsy (TLE) were injected into frog oocytes. Within a few hours, these oocytes acquired GAB[A.sub.A] receptors that generated GABA currents with an unusual run-down, which was inhibited by orthovanadate and okadaic acid. In contrast, receptors derived from membranes of a nonepileptic hippocampal uncus, membranes from mouse brain, or recombinant rat [alpha]1[beta]2[gamma]2-GABA receptors exhibited a much less pronounced GABA-current rundown. Moreover, the GAB[A.sub.A] receptors of pyramidal neurons in temporal neocortex slices from the same six epileptic patients exhibited a stronger run-down than the receptors of rat pyramidal neurons. Interestingly, the GAB[A.sub.A] receptors of neighboring glial cells remained substantially stable after repetitive activation. Therefore, the excessive GABA-current run-down observed in the membrane-injected oocytes recapitulates essentially what occurs in neurons, rather than in glial cells. Quantitative RT-PCR analyses from the same TLE neocortex specimens revealed that GAB[A.sub.A]receptor [beta]1, [beta]2, [beta]3, and [gamma]2 subunit mRNAs were significantly overexpressed (8- to 33-fold) compared with control autopsy tissues. Our results suggest that an abnormal GABA-receptor subunit transcription in the TLE brain leads to the expression of run-down-enhanced GAB[A.sub.A] receptors. Blockage of phospbatases stabilizes the TLE GAB[A.sub.A] receptors and strengthens GABAergic inhibition. It may be that this process can be targeted to develop new treatments for intractable epilepsy. temporal lobe epilepsy | microtransplantation into Xenopus oocyte | okadaic acid | [gamma]-aminobutyric acid-current run-down | human tissue slices

Published
2004

12. Utilità delle sequenze turbo-flair e analisi volumetrica della regione ippocampale nella valutazione del paziente con epilessia temporale farmaco-resistente

Author

Ferone, E., Pierallini, A., Bonamini, M., Bozzao, A., Quarato, P.P., Giallonardo, M.T., and Fantozzi, L.M.

Abstract

The aim of this study was to evaluate the hippocampal region using Fluid Attenuation Inversion Recovery sequences (Turbo-FLAIR) to detect signal intensity abnormalities, and volumetric sequences to detect cortical thickness changes, in patients with drug-resistant temporal epilepsy.We evaluated 30 patients with drug-resistant temporal epilepsy with a 1.5 Tesla unit (NT 15 Philips Gyroscan). Conventional SE, Turbo SE, IR, Turbo-FLAIR, volumetric 3D sequences on coronal plane, PD, T2weighted SE sequences on axial plane, T1-weighted SE on sagittal plane / were performed. Signal intensity and volumetric computerized measurements were obtained using the SUN system. Differences in signal intensity values between the two hippocampal regions were found in 18 patients with Turbo-FLAIR sequences. In 6 of the sepatients no significant differences in computerized evaluation of signal intensity were detected with either conventional or Turbo-SE sequences. Volumetric analysis showed hippocampal cortex thinning in 9 out of 18 patients with hippocampal signal intensity abnormalities.Turbo -FLAIR provided the best sequences for the detection of signal intensity changes in the hippocampal region. Such changes are strongly suggestive of hippocampal sclerosis, especially when associated with cortical atrophy.

Published
1997
Full Text
View/download PDF

14. Adjunctive Brivaracetam in Older Patients with Focal Seizures: Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST)

Author

Simona Lattanzi, 1, Michele Ascoli, 2, Laura Canafoglia, 3, 4 5, Maria Paola Canevini, Sara Casciato, 6, Emanuele Cerulli Irelli, 7, Valentina Chiesa, 4, Filippo Dainese, 8, Giovanni De Maria, 9, Giuseppe Didato 10, Giancarlo Di Gennaro, 6, Giovanni Falcicchio 11, Martina Fanella, 7, Massimo Gangitano 12, Angela La Neve 11, Oriano Mecarelli, 7, Elisa Montalenti 13, Alessandra Morano, 7, Federico Piazza 14, Chiara Pizzanelli 15, Patrizia Pulitano, 7, Federica Ranzato 16, Eleonora Rosati 17, Laura Tassi 18, Carlo Di Bonaventura, 7, BRIVAFIRST Group Collaborators, Affiliations collapse Collaborators BRIVAFIRST Group: Angela Alicino, Giovanni, Assenza, Federica, Avorio, Valeria, Badioni, Paola, Banfi, Emanuele, Bartolini, Luca Manfredi Basili, Vincenzo, Belcastro, Simone, Beretta, Irene, Berto, Martina, Biggi, Giuseppe, Billo, Giovanni, Boero, Paolo, Bonanni, Jole, Bongiorno, Francesco, Brigo, Emanuele, Caggia, Claudia, Cagnetti, Carmen, Calvello, Edward, Cesnik, Gigliola, Chianale, Domenico, Ciampanelli, Roberta, Ciuffini, Dario, Cocito, Donato, Colella, Margerita, Contento, Cinzia, Costa, Eduardo, Cumbo, Alfredo, D'Aniello, Francesco, Deleo, Jacopo, C DiFrancesco, Roberta Di Giacomo, Alessandra Di Liberto, Elisabetta, Domina, Francesco, Donato, Fedele, Dono, Vania, Durante, Maurizio, Elia, Anna, Estraneo, Giacomo, Evangelista, Maria Teresa Faedda, Ylenia, Failli, Elisa, Fallica, Jinane, Fattouch, Alessandra, Ferrari, Ferreri, Florinda, Giacomo, Fisco, Davide, Fonti, Francesco, Fortunato, Nicoletta, Foschi, Teresa, Francavilla, Rosita, Galli, Sara, Gasparini, Stefano, Gazzina, Anna Teresa Giallonardo, Filippo Sean Giorgi, Loretta, Giuliano, Francesco, Habetswallner, Francesca, Izzi, Kassabian, Benedetta, Lorenzo, Kiferle, Angelo, Labate, Concetta, Luisi, Matteo, Magliani, Giulia, Maira, Luisa, Mari, Daniela, Marino, Addolorata, Mascia, Alessandra, Mazzeo, Stefano, Meletti, Chiara, Milano, Annacarmen, Nilo, Biagio, Orlando, Francesco, Paladin, Maria Grazia Pascarella, Chiara, Pastori, Giada, Pauletto, Alessia, Peretti, Gabriella, Perri, Marianna, Pezzella, Marta, Piccioli, Pietro, Pignatta, Nicola, Pilolli, Francesco, Pisani, Laura Rosa Pisani, Fabio, Placidi, Patrizia, Pollicino, Vittoria, Porcella, Monica, Puligheddu, Stefano, Quadri, Pier Paolo Quarato, Rui, Quintas, Rosaria, Renna, Adriana, Rum, Enrico Michele Salamone, Ersilia, Savastano, Maria, Sessa, David, Stokelj, Elena, Tartara, Mario, Tombini, Gemma, Tumminelli, Anna Elisabetta Vaudano, Ilaria, Viganò, Emanuela, Viglietta, Aglaia, Vignoli, Flavio, Villani, Elena, Zambrelli, Lelia, Zummo, Lattanzi S., Canafoglia L., Canevini M.P., Casciato S., Cerulli Irelli E., Chiesa V., Dainese F., De Maria G., Didato G., Falcicchio G., Fanella M., Ferlazzo E., Gangitano M., Giorgi F.S., La Neve A., Mecarelli O., Montalenti E., Morano A., Piazza F., Pulitano P., Quarato P.P., Ranzato F., Rosati E., Tassi L., and Di Bonaventura C.

Subjects
Antiseizure medication, Epilepsy, Settore MED/26, Pyrrolidinones, Focal seizures, Treatment Outcome, Drug Therapy, Double-Blind Method, Italy, Seizures, Brivaracetam, Combination, Aged, Drug Therapy, Combination, Humans, Retrospective Studies, Anticonvulsants, Pharmacology (medical), Settore MED/26 - Neurologia, Geriatrics and Gerontology
Abstract

BACKGROUND: The management of epilepsy in older adults has become part of daily practice because of an aging population. Older patients with epilepsy represent a distinct and more vulnerable clinical group as compared with younger patients, and they are generally under-represented in randomized placebo-controlled trials. Real-world studies can therefore be a useful complement to characterize the drug's profile. Brivaracetam is a rationally developed compound characterized by high-affinity binding to synaptic vesicle protein 2A and approved as adjunctive therapy for focal seizures in adults with epilepsy. OBJECTIVE: The aim of this study was to assess the 12-month effectiveness and tolerability of adjunctive brivaracetam in older patients (≥65 years of age) with epilepsy treated in a real-world setting. METHODS: The BRIVAFIRST (BRIVAracetam add-on First Italian netwoRk STudy) was a 12-month retrospective multicenter study including adult patients prescribed adjunctive brivaracetam. Effectiveness outcomes included the rates of seizure response (≥50% reduction in baseline seizure frequency), seizure freedom, and treatment discontinuation. Safety and tolerability outcomes included the rate of treatment discontinuation due to adverse events and the incidence of adverse events. Data were compared for patients aged ≥65 years of age ('older') vs those aged

Published
2022

15. Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST)

Author

Simona Lattanzi, Laura Canafoglia, Maria Paola Canevini, Sara Casciato, Emanuele Cerulli Irelli, Valentina Chiesa, Filippo Dainese, Giovanni De Maria, Giuseppe Didato, Giancarlo Di Gennaro, Giovanni Falcicchio, Martina Fanella, Edoardo Ferlazzo, Massimo Gangitano, Angela La Neve, Oriano Mecarelli, Elisa Montalenti, Alessandra Morano, Federico Piazza, Chiara Pizzanelli, Patrizia Pulitano, Federica Ranzato, Eleonora Rosati, Laura Tassi, Carlo Di Bonaventura, Angela Alicino, Michele Ascoli, Giovanni Assenza, Federica Avorio, Valeria Badioni, Paola Banfi, Emanuele Bartolini, Luca Manfredi Basili, Vincenzo Belcastro, Simone Beretta, Irene Berto, Martina Biggi, Giuseppe Billo, Giovanni Boero, Paolo Bonanni, Jole Bongorno, Francesco Brigo, Emanuele Caggia, Claudia Cagnetti, Carmen Calvello, Edward Cesnik, Gigliola Chianale, Domenico Ciampanelli, Roberta Ciuffini, Dario Cocito, Donato Colella, Margerita Contento, Cinzia Costa, Eduardo Cumbo, Alfredo D'Aniello, Francesco Deleo, Jacopo C DiFrancesco, Roberta Di Giacomo, Alessandra Di Liberto, Elisabetta Domina, Fedele Dono, Vania Durante, Maurizio Elia, Anna Estraneo, Giacomo Evangelista, Maria Teresa Faedda, Ylenia Failli, Elisa Fallica, Jinane Fattouch, Alessandra Ferrari, Florinda Ferreri, Giacomo Fisco, Davide Fonti, Francesco Fortunato, Nicoletta Foschi, Teresa Francavilla, Rosita Galli, Stefano Gazzina, Anna Teresa Giallonardo, Filippo Sean Giorgi, Loretta Giuliano, Francesco Habetswallner, Francesca Izzi, Benedetta Kassabian, Angelo Labate, Concetta Luisi, Matteo Magliani, Giulia Maira, Luisa Mari, Daniela Marino, Addolorata Mascia, Alessandra Mazzeo, Chiara Milano, Stefano Meletti, Annacarmen Nilo, Biagio Orlando, Francesco Paladin, Maria Grazia Pascarella, Chiara Pastori, Giada Pauletto, Alessia Peretti, Gabriella Perri, Marianna Pezzella, Marta Piccioli, Pietro Pignatta, Nicola Pilolli, Francesco Pisani, Laura Rosa Pisani, Fabio Placidi, Patrizia Pollicino, Vittoria Porcella, Silvia Pradella, Monica Puligheddu, Stefano Quadri, Pier Paolo Quarato, Rui Quintas, Rosaria Renna, Giada Ricciardo Rizzo, Adriana Rum, Enrico Michele Salamone, Ersilia Savastano, Maria Sessa, David Stokelj, Elena Tartara, Mario Tombini, Gemma Tumminelli, Anna Elisabetta Vaudano, Maria Ventura, Ilaria Viganò, Emanuela Viglietta, Aglaia Vignoli, Flavio Villani, Elena Zambrelli, Lelia Zummo, Lattanzi S., Canafoglia L., Canevini M.P., Casciato S., Cerulli Irelli E., Chiesa V., Dainese F., De Maria G., Didato G., Di Gennaro G., Falcicchio G., Fanella M., Ferlazzo E., Gangitano M., La Neve A., Mecarelli O., Montalenti E., Morano A., Piazza F., Pizzanelli C., Pulitano P., Ranzato F., Rosati E., Tassi L., Di Bonaventura C., Alicino A., Ascoli M., Assenza G., Avorio F., Badioni V., Banfi P., Bartolini E., Basili L.M., Belcastro V., Beretta S., Berto I., Biggi M., Billo G., Boero G., Bonanni P., Bongiorno J., Brigo F., Caggia E., Cagnetti C., Calvello C., Cesnik E., Chianale G., Ciampanelli D., Ciuffini R., Cocito D., Colella D., Contento M., Costa C., Cumbo E., D'Aniello A., Deleo F., DiFrancesco J.C., Di Giacomo R., Di Liberto A., Domina E., Dono F., Durante V., Elia M., Estraneo A., Evangelista G., Faedda M.T., Failli Y., Fallica E., Fattouch J., Ferrari A., Ferreri F., Fisco G., Fonti D., Fortunato F., Foschi N., Francavilla T., Galli R., Gazzina S., Giallonardo A.T., Giorgi F.S., Giuliano L., Habetswallner F., Izzi F., Kassabian B., Labate A., Luisi C., Magliani M., Maira G., Mari L., Marino D., Mascia A., Mazzeo A., Milano C., Meletti S., Nilo A., Orlando B., Paladin F., Pascarella M.G., Pastori C., Pauletto G., Peretti A., Perri G., Pezzella M., Piccioli M., Pignatta P., Pilolli N., Pisani F., Pisani L.R., Placidi F., Pollicino P., Porcella V., Pradella S., Puligheddu M., Quadri S., Quarato P.P., Quintas R., Renna R., Rizzo G.R., Rum A., Salamone E.M., Savastano E., Sessa M., Stokelj D., Tartara E., Tombini M., Tumminelli G., Vaudano A.E., Ventura M., Vigano I., Viglietta E., Vignoli A., Villani F., Zambrelli E., and Zummo L.

Subjects
Adult, Antiseizure medication, Brivaracetam, Cerebrovascular diseases, Focal seizures, Stroke, Settore MED/26, Antiseizure medication, Brivaracetam, Focal seizures, Stroke, Cerebrovascular diseases, Double-Blind Method, Drug Therapy, Seizures, Humans, Aged, Retrospective Studies, Epilepsy, General Medicine, Middle Aged, Pyrrolidinones, Treatment Outcome, Neurology, Italy, Combination, Anticonvulsants, Drug Therapy, Combination, Neurology (clinical)
Abstract

Objective: Post-stroke epilepsy (PSE) is one of the most common causes of acquired epilepsy and accounts for about 10-15% of all newly diagnosed epilepsy cases. However, evidence about the clinical profile of antiseizure medications in the PSE setting is currently limited. Brivaracetam (BRV) is a rationally developed compound characterized by high-affinity binding to synaptic vesicle protein 2A. The aim of this study was to assess the 12-month effectiveness and tolerability of adjunctive BRV in patients with PSE treated in a real-world setting. Methods: This was a subgroup analysis of patients with PSE included in the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). The BRIVAFIRST was a 12-month retrospective, multicentre study including adult patients prescribed adjunctive BRV. Effectiveness outcomes included the rates of seizure response (≥50% reduction in baseline seizure frequency), seizure‐freedom, and treatment discontinuation. Safety and tolerability outcomes included the rate of treatment discontinuation due to adverse events (AEs) and the incidence of AEs. Results: Patients with PSE included in the BRIVAFIRST were 75 and had a median age of 57 (interquartile range, 42-66) years. The median daily doses of BRV at 3, 6, and 12 months from starting treatment were 100 (100-150) mg, 125 (100-200) mg and 100 (100-200) mg, respectively. At 12 months, 32 (42.7%) patients had a reduction in their baseline seizure frequency by at least 50%, and the seizure freedom rates was 26/75 (34.7%). During the 1-year study period, 10 (13.3%) patients discontinued BRV. The reasons of treatment withdrawal were insufficient efficacy in 6 (8.0%) patients and poor tolerability in 4 (5.3%) patients. Adverse events were reported by 13 (20.3%) patients and were rated as mild in 84.6% and moderate in 15.4% of cases. Significance: Adjunctive BRV was efficacious and generally well-tolerated when used in patients with PSE in clinical practice. Adjunctive BRV can be a suitable therapeutic option for patients with PSE.

Published
2022

16. Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)

Author

Lattanzi, S., Canafoglia, L., Canevini, M. P., Casciato, S., Chiesa, V., Dainese, F., De Maria, G., Didato, G., Falcicchio, G., Fanella, M., Ferlazzo, E., Fisco, G., Gangitano, M., Giallonardo, A. T., Giorgi, F. S., La Neve, A., Mecarelli, O., Montalenti, E., Piazza, F., Pulitano, P., Quarato, P. P., Ranzato, F., Rosati, E., Tassi, L., Di Bonaventura, C., Alicino, A., Ascoli, M., Assenza, G., Avorio, F., Badioni, V., Banfi, P., Bartolini, E., Basili, L. M., Belcastro, V., Beretta, S., Berto, I., Biggi, M., Billo, G., Boero, G., Bonanni, P., Bongorno, J., Brigo, F., Caggia, E., Cagnetti, C., Calvello, C., Irelli, E. C., Cesnik, E., Chianale, G., Ciampanelli, D., Ciuffini, R., Cocito, D., Colella, D., Contento, M., Costa, C., Cumbo, E., D'Aniello, A., Deleo, F., Difrancesco, J. C., Di Gennaro, G., Di Giacomo, R., Di Liberto, A., Domina, E., Donato, F., Dono, F., Durante, V., Elia, M., Estraneo, A., Evangelista, G., Faedda, M. T., Failli, Y., Fallica, E., Fattouch, J., Ferrari, A., Ferreri, F., Fonti, D., Fortunato, F., Foschi, N., Francavilla, T., Galli, R., Gazzina, S., Giuliano, L., Habetswallner, F., Izzi, F., Kassabian, B., Labate, A., Luisi, C., Magliani, M., Maira, G., Mari, L., Marino, D., Mascia, A., Mazzeo, A., Meletti, S., Morano, A., Nilo, A., Orlando, B., Paladin, F., Pascarella, M. G., Pastori, C., Pauletto, G., Peretti, A., Perri, G., Pezzella, M., Piccioli, M., Pignatta, P., Pilolli, N., Pisani, F., Pisani, L. R., Placidi, F., Pollicino, P., Porcella, V., Pradella, S., Puligheddu, M., Quadri, S., Quintas, R., Renna, R., Rossi, J., Rum, A., Salamone, E. M., Savastano, E., Sessa, M., Stokelj, D., Tartara, E., Tombini, M., Tumminelli, G., Ventura, M., Vigano, I., Viglietta, E., Vignoli, A., Villani, F., Zambrelli, E., Zummo, L., Lattanzi S., Canafoglia L., Canevini M.P., Casciato S., Chiesa V., Dainese F., De Maria G., Didato G., Falcicchio G., Fanella M., Ferlazzo E., Fisco G., Gangitano M., Giallonardo A.T., Giorgi F.S., La Neve A., Mecarelli O., Montalenti E., Piazza F., Pulitano P., Quarato P.P., Ranzato F., Rosati E., Tassi L., and Di Bonaventura C.

Subjects
medicine.medical_specialty, business.industry, Context (language use), Brivaracetam, medicine.disease, Discontinuation, law.invention, Psychiatry and Mental health, Epilepsy, Randomized controlled trial, Tolerability, focal epilepsy, add-on therapy, seizure, law, Concomitant, Internal medicine, Medicine, Pharmacology (medical), Neurology (clinical), Levetiracetam, Original Research Article, business, medicine.drug
Abstract

Background: In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Studies performed in a naturalistic setting are a useful complement to characterize the drug profile. Objective: This multicentre study assessed the effectiveness and tolerability of adjunctive BRV in a large population of patients with focal epilepsy in the context of real-world clinical practice. Methods: The BRIVAFIRST (BRIVAracetam add-on First Italian netwoRk STudy) was a retrospective, multicentre study including adult patients prescribed adjunctive BRV. Patients with focal epilepsy and 12-month follow-up were considered. Main outcomes included the rates of seizure‐freedom, seizure response (≥50% reduction in baseline seizure frequency), and treatment discontinuation. The incidence of adverse events (AEs) was also considered. Analyses by levetiracetam (LEV) status and concomitant use of strong enzyme-inducing antiseizure medications (EiASMs) and sodium channel blockers (SCBs) were performed. Results: A total of 1029 patients with a median age of 45years (33–56) was included. At 12 months, 169 (16.4%) patients were seizure-free and 383 (37.2%) were seizure responders. The rate of seizure freedom was 22.3% in LEV-naive patients, 7.1% in patients with prior LEV use and discontinuation due to insufficient efficacy, and 31.2% in patients with prior LEV use and discontinuation due to AEs (p&nbsp

Published
2021

17. Temporal lobe epilepsy surgery in children and adults: A multicenter study

Author

Barba, Carmen, Cossu, Massimo, Guerrini, Renzo, Di Gennaro, Giancarlo, Villani, Flavio, De Palma, Luca, Grisotto, Laura, Consales, Alessandro, Battaglia, Domenica, Zamponi, Nelia, d’Orio, Piergiorgio, Revay, Martina, Rizzi, Michele, Casciato, Sara, Esposito, Vincenzo, Quarato, Pier Paolo, Di Giacomo, Roberta, Didato, Giuseppe, Pastori, Chiara, Pavia, Giusy Carfi, Pellacani, Simona, Matta, Giulia, Pacetti, Mattia, Tamburrini, Gianpiero, Cesaroni, Elisabetta, Colicchio, Gabriella, Vatti, Giampaolo, Asioli, Sofia, Caulo, Massimo, Marras, Carlo Efisio, Tassi, Laura, D’Aniello, Alfredo, Morace, Roberta, De Curtis, Marco, Deleo, Francesca, Giordano, Flavio, De Benedictis, Alessandro, Prato, Giulia, Perulli, Marco, Barba C., Cossu M., Guerrini R., Di Gennaro G., Villani F., De Palma L., Grisotto L., Consales A., Battaglia D., Zamponi N., d'Orio P., Revay M., Rizzi M., Casciato S., Esposito V., Quarato P.P., Di Giacomo R., Didato G., Pastori C., Carfi Pavia G., Pellacani S., Matta G., Pacetti M., Tamburrini G., Cesaroni E., Colicchio G., Vatti G., Asioli S., Caulo M., Marras C.E., and Tassi L.

Subjects
0301 basic medicine, Male, Electroencephalography, Neuropsychological Tests, Hippocampus, Neurosurgical Procedures, Epilepsy, 0302 clinical medicine, Postoperative Complications, Cognition, Epilepsy surgery, Child, seizure outcome, medicine.diagnostic_test, Age Factors, Prognosis, Temporal Lobe, Malformations of Cortical Development, Neurology, Child, Preschool, epilepsy surgery, Anticonvulsants, Female, Adult, medicine.medical_specialty, Referral, Adolescent, Temporal lobe, 03 medical and health sciences, Young Adult, Settore MED/39 - NEUROPSICHIATRIA INFANTILE, children, Internal medicine, Early Medical Intervention, medicine, Humans, Preschool, Retrospective Studies, Hippocampal sclerosis, Sclerosis, business.industry, Magnetic resonance imaging, Odds ratio, cognitive outcome, medicine.disease, 030104 developmental biology, Epilepsy, Temporal Lobe, Neurology (clinical), business, 030217 neurology & neurosurgery
Abstract

Objective: To assess seizure and cognitive outcomes and their predictors in children (

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results